Diplomat dispensing Novartis’ Rydapt

FLINT, Mich. — Diplomat Pharmacy on Thursday announced that it had added a new drug to the roster of its oncology treatments. The specialty pharmacy chain will be dispensing Novartis’ Rydapyt (midostaurin), a treatment for newly diagnosed acute myeloid leukemia that is positive for an FLT3 mutation detected by a test approved by the Food and Drug Administration.

The oral therapy is administered twice daily for adults with an FLT3 mutation-positive acute myeloid leukemia diagnosis. The FDA also approved the drug as a treatment for aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm and mast cell leukemia.

“We are excited about the recent approval of RYDAPT® (midostaurin) to treat newly diagnosed FLT3-mutated AML patients. It opens a new treatment strategy for these patients,” Diplomat president Paul Urick said. “We understand cancer treatments can be complex. Through our coordinated care team, we are eager to provide patients this encouraging new therapy option with our expertise and personal support.”